Celia Morgan

Clinical Psychopharmacologist

Data updated

Papers

10 publications

Trials

0 clinical trials

Links

Research Footprint

Celia Morgan appears in 10 tracked papers (2014–2025), most studied alongside Ketamine, Ayahuasca and MDMA, across Substance Use Disorders (SUD), Depressive Disorders and Alcohol Use Disorder (AUD).

Most-cited paper: Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder (164 citations).

Frequent co-authors: Will Lawn, Valerie Curran and David Nutt.

Background & Research

Celia J. A. Morgan is a clinical psychopharmacologist whose work spans experimental psychopharmacology, naturalistic studies and clinical trials focused on entactogens (MDMA/ecstasy) and dissociative agents (ketamine). She has led and contributed to multiple studies characterising the socio-emotional effects of MDMA — including empathy, cooperative behaviour and perception of trustworthiness — and has applied these mechanistic insights to clinical research on psychedelic-assisted treatments for substance use disorders.

Her recent research portfolio includes trials and qualitative studies investigating adjunctive ketamine with relapse-prevention psychological therapy for alcohol use disorder, and exploratory and Bayesian analyses of MDMA-assisted psychotherapy outcomes for alcohol use disorder. Morgan's methodological range — from lab-based behavioural pharmacology to randomised clinical trials and patient-centred qualitative work — has contributed to understanding both the acute interpersonal effects of entactogens and the therapeutic potential of these compounds in addiction psychiatry.

Affiliations

Institutions, companies, and organisations Celia Morgan is associated with.